Online ISSN: 2515-8260

Keywords : Adjuvant chemotherapy

Surgical Outcome Of Stage Iii A Carcinoma Breast In Patient With Taxane Based Chemotherapy -Neoadjuvant Vs Adjuvant Chemotherapy Setting

Dr. Poosapati D. Devasilpa; Dr. Raju K. Shinde

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 11, Pages 3668-3674

Background-Labc: is one of the common breast malignancies at present. With the increasing incidence even the treatment protocols have changed dramatically. Along with adjuvant there is introduction of neoadjuvant chemotherapy which offers the advantage of downgrading the tumor before surgical resection. Downgrading the tumor before surgery is going to make the tumor inoperable to operable.
One of the major advantages of this is patient becomes liable for breast conserving surgery (B CS).Butin few cases where the margins are not well demarcated and there is active local infiltration 1st patient is planned for operation followed by cycles of chemotherapy. This study mainly aims at comparison between the outcomes of neoadjuvant and adjuvant chemotherapy using taxane based drugs.
Objectives –
 To study the outcome in relation with the molecular subtype
 To study the outcome of stage IIIA patients in Neoadjuvant setting
 To study the outcome of stage IIIA patients in Adjuvant setting
Methodology-This study will be performed in AVBRH where total of 40 patients will be taken up for the study. Women with LABC belonging to stage 3A will be chosen for this study. A written and an informed consent will be taken from the patient. Labc will be diagnosed by means of fnac and true cut biopsy of the breast tissue.Patients will be subjected to either neoadjuvant or adjuvant chemotherapy with taxane based drugs depending upon the presentation of the LABC.
Results- In the above study the most probable outcome is that neoadjuvant chemotherapy will have better surgical outcomes as neoadjuvant chemotherapy aims at downgrading the tumor with possibility of breast conserving surgery. Adjuvant chemotherapy is a more aggressive treatment which may not be associated with that of better outcomes, with more chances of developing post chemotherapy complications.
Conclusion- This study will be a comparison study between the surgical outcomes of neoadjuvant and adjuvant-based chemotherapy using taxane based chemotherapy in stage 3a of breast cancer. Most probably neoadjuvant paclitaxel based chemotherapy will be a better option because it will be associated with lesser post chemotherapeutic complications and with a chance of patient undergoing BCS (breast conserving surgery).